Key facts
- It has raised $150K; the latest was Seed Round ($150K) in Apr 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for NeuroReformer
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroReformer are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroReformer
Developer of a neural recovery device designed for neurocellular rehabilitation and axonal repair. The company's devices use micro-precision hardware and AI-calibrated frequencies to replicate biological signals that resonate with atrophied nerve and muscle cells, facilitating axonal repair and improving neuroconnectivity, enabling physical therapy clinics and athletes to accelerate tissue repair.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2022
- Website
- neuroreformer.com/
- Ownership
- Privately Held (backing)
NeuroReformer doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroReformer shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroReformer in its N-PORT filings yet. We sweep new filings monthly.